Nemolizumab Cuts Itch 56–72% in Children Aged 2–11 in Phase 2
![<![CDATA[Q&A: What Phase 2 Nemolizumab Data Mean for Young Children With Eczema]]>](/media/85/851be3c34f2b3fd1.1280.webp)
Between 56% and 72% of children aged 2 to 11 years with moderate to severe atopic dermatitis achieved at least a 4-point reduction on the Peak Pruritus Numerical Rating Scale (PP-NRS, a 0–10 itch severity measure) by week 16 of treatment with nemolizumab, according to phase 2 data presented by Galderma at the Pediatric Dermatology Research Alliance (PeDRA) 2026 Annual Conference. The agent, an interleukin-31 (IL-31) receptor alpha antagonist, is currently approved only for patients 12 years and older.
The multicenter, open-label study enrolled children across three cohorts stratified by age and weight, each receiving weight-tiered nemolizumab plus topical corticosteroids through week 52. Response rates held steady or rose further at one year. Roughly three-quarters of participants had moderate disease at baseline and 25% had severe disease.
"The results seen in this phase 2 study of nemolizumab are promising," said Lawrence Eichenfield, MD, professor of dermatology and pediatrics at the University of California, San Diego School of Medicine and chief of pediatric dermatology at Rady Children's Hospital-San Diego, who led the abstract.
How should clinicians read itch in a 2-year-old?
Eichenfield drew a sharp line between age groups. A 10-year-old can report a 0-to-10 worst-itch score; a 2-year-old cannot. "A 0-to-10 worst itch in the last 24 hours isn't going to mean anything to a 2-year-old," he said. The study relied on surrogate measures — a worst itch-scratch score reported by parents or other caretakers — which prior research has validated as highly reliable.
The analysis examined two cohorts in detail: children aged 2 to 6 and those aged 7 to 11. Itch fell rapidly — a 40% to 60% decrease early in treatment — then plateaued. "They were mostly pretty stable from almost 8 weeks, even before the 16-week time course, through the 1-year course of the study," Eichenfield said. Dosing consisted of monthly injections.
What did sleep and quality-of-life data show?
Sleep Disturbance Numerical Rating Scale scores dropped 70% to 78% across cohorts at week 16 and kept improving through one year. Eichenfield called sleep a core endpoint. A child awake at night wakes the household, and a tired toddler or 11-year-old performs worse at school and preschool the next day — a compounding burden he said dermatologists should probe at every visit.
In children 4 years and older, mean Children's Dermatology Life Quality Index (CDLQI) scores fell 10.7 to 12.0 points from baseline at week 52. Baseline scores of 15 to 20 signal substantial disease impact on daily life. Eichenfield cautioned that instruments such as the CDLQI and the Infants' Dermatitis Quality of Life Index are research composites, not practical clinic tools — though they convey how broadly a drug calms the downstream effects of uncontrolled eczema.
What are the study's limits?
Each cohort contained only somewhere in the 30s of patients. All participants received topical corticosteroids alongside the biologic. The design was open-label with no comparison group, which, Eichenfield noted, makes enthusiasm easier to come by. "It's easy to be very positive about how the patients are doing," he said.
Galderma reported no new safety signals, and Eichenfield said the safety profile matched what adolescent and adult trials previously showed, with no significant adverse events in the protocol. Existing pharmacokinetic data already demonstrated appropriate weight-based dose matching.
What comes next?
Systemic options for children under 12 with moderate to severe atopic dermatitis remain limited, and nemolizumab has not moved toward approval below that age. Eichenfield framed these data as the next step toward a label extension, noting the IL-31 blockade mechanism is unique in combining anti-inflammatory and anti-itch action. Whether open-label gains survive randomized, controlled testing in younger children will determine whether regulators follow.
Source: dermatologytimes.com
Amara Osei
Show full bio
Correspondent covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.